沙格列汀联合吡格列酮治疗血糖控制欠佳2型糖尿病疗效观察

Shah Glenn Dean combined with pioglitazone for the treatment of poor glycemic control in type 2 diabetes mellitus curative effect observation

选取2013年2月~2014年12月期间我院收治的68例血糖控制不佳的2型糖尿病患者,分为观察组(n=34)和对照组(n=34)。对照组治疗方案维持不变,观察组在原有基础上加用沙格列汀及吡格列酮。结果:治疗前,两组患者的GLU、2hPG、HbA_(1c)、FINS、FCP、homa-β和homa-IR、Homa-IR(CP)比较无统计学意义(P>0.05);治疗后,观察组患者的GLU、2hPG、HbA_(1c)、FINS和homa-IR、Homa-IR(CP)水平降低,FCP、homa-β升高(P<0.05);对照组无明显变化(P>0.05);FCP显著升高(P<0.05);观察组患者的的GLU、2hPG、HbA_(1c)、FINS和homa-IR、Homa-IR(CP)水平低于对照组,FCP、homa-β高于对照组(P<0.05);两组不良反应无统计学意义(P>0.05)。结论:难治性糖尿病患者可以加用沙格列汀吡格列酮治疗安全有效。

68 cases of type 2 diabetes with poor glycemic control in our hospital form February 2013 - 2014 December were selected and randomly divided into observation group （ n = 34 ） and control group （ n = 34 ）. The control group treatment remained unchanged, the observation group on the basis of the original with Shah Glenn Dean and pioglitazone. Results Before treatment,the two groups of patients Glu, 2hPG, HbAlc, fins, HOMA beta and I-IOMA-IR had no statistical significance （ P 〉 0. 05 ） ; after treatment were observed group of patients with Glu ,2hPG, HbAlc, fins and HOMA-IR levels decreased significantly, HOMA beta significantly increased, the difference is statistically significant （ P 〈 0. 05 ） ; patients in control group were treated with Glu, 2hPG, HbAlc, fins, HOMA beta and HOMA-IR levels no significant change （ P 〉 0. 05 ） ; observation group patients Glu ,2hPG, HbAlc, fins and HOMA-IR level lower than that of the control group, the HOMA beta higher than control group, and the difference is statistically significant （P 〈 0. 05 ） ; The incidence of adverse reactions in the two groups was not statistically sig- nificant （P 〉 0. 05 ）. Conclusion Patients with refractory diabetes mellitus combined with pioglitazone can be safe and effective in the treatment of Shah Glenn Dean.